These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10810443)

  • 1. Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids.
    Kailajärvi M; Ahokoski O; Virtanen A; Salminen E; Irjala K
    Anticancer Res; 2000; 20(2B):1323-7. PubMed ID: 10810443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early effects of 5-fluorouracil, epirubicin and cyclophosphamide therapy on common laboratory tests.
    Kailajärvi M; Ahokoski O; Virtanen A; Salminen E; Irjala K
    Anticancer Res; 2001; 21(4B):2867-72. PubMed ID: 11712778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Postoperative changes in serum lipid levels of breast cancer and adjuvant chemotherapy].
    Morimoto K; Koh M
    Gan To Kagaku Ryoho; 2004 Oct; 31(10):1517-24. PubMed ID: 15508443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Coenzyme Q(10), Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles.
    Yuvaraj S; Premkumar VG; Shanthi P; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Breast Cancer Res Treat; 2009 Mar; 114(2):377-84. PubMed ID: 18427979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
    Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
    Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin.
    Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Cancer Chemother Pharmacol; 2008 May; 61(6):933-41. PubMed ID: 17668211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
    Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty liver and transaminase changes with adjuvant tamoxifen therapy.
    Liu CL; Huang JK; Cheng SP; Chang YC; Lee JJ; Liu TP
    Anticancer Drugs; 2006 Jul; 17(6):709-13. PubMed ID: 16917217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
    Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
    Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in laboratory test results during adjuvant breast cancer treatment.
    Kailajärvi M; Ahokoski O; Virtanen A; Salminen E; Irjala K
    Clin Chem Lab Med; 2000 May; 38(5):443-51. PubMed ID: 10952229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.